This article reports the results of a study that evaluated the combination of the MEK1/2 inhibitor binimetinib and the EGFR inhibitor panitumumab in patients with RAS -mutant or BRAF wild type/RAS wild-type metastatic colorectal cancer. The gene discussed is EGFR; the disease is metastatic colorectal cancer.